Posted in | News | Carbon Credit | Hydrogen

MHI Invests in Syzygy Plasmonics to Advance Hydrogen Production and CO2 Utilization

Mitsubishi Heavy Industries, Ltd. (MHI) announced today that it has invested in Syzygy Plasmonics, Inc. (Syzygy), a startup company headquartered in Houston, Texas, that is developing photocatalytic technology for hydrogen production and CO2 utilization solutions. The investment has been executed through Mitsubishi Heavy Industries America, Inc. (MHIA).

Image Credit: Mitsubishi Heavy Industries, Ltd.

Founded in 2018 to commercialize a radical new technology developed at Houston's Rice University, Syzygy builds reactors that use light instead of combustion to electrify chemical manufacturing and power a cleaner, safer world. When powered with renewable electricity, this tunable technology is designed to reduce both cost and emissions associated with many different chemical reactions.

Syzygy's solutions enable manufacturers to produce zero-emissions hydrogen from ammonia and low-emissions hydrogen from a combustion-free form of steam methane reforming. They also provide efficient means for converting methane and captured CO2 into sustainable fuels and methanol.

By collaborating with and investing in partners with innovative technologies, MHI Group is working to build a hydrogen ecosystem and a CO2 ecosystem that can contribute to the realization of a decarbonized society. Through this investment, Mitsubishi Heavy Industries will support Syzygy's efforts to develop innovative alternative technologies that will lead to the diversification of both ecosystems.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.